U.S. mRNA Synthesis Raw Materials Market Size, Share & Trends Analysis Report, By Type (Capping Agents, Nucleotides, Plasmid DNA), By Application (Vaccine, Therapeutics), By End-use, And Segment Forecasts, 2024 - 2030
This report can be delivered to the clients within 2 Business Days
U.S. mRNA Synthesis Raw Materials Market Growth & Trends
The U.S. mRNA synthesis raw materials market size is anticipated to reach USD 976.2 million by 2030 and is growing at a CAGR of 2.93% from 2024 to 2030, according to a new report by Grand View Research, Inc. The major factors driving the market include growing academic & industrial interest in mRNA technology, advantages of mRNA vaccines, and increasing funding for mRNA research.
The development and widespread application of mRNA vaccines for the COVID-19 disease made 2020 a watershed year for mRNA technology platforms. At the end of 2019, the market value of the five publicly traded mRNA platform companies was over USD 15 billion. This capitalization was about USD 300 billion in August 2021. Recent major investment has been attracted due to the success of mRNA's COVID-19 vaccines, promoting the creation of medications to treat numerous diseases. The upsurge in clinical trials and the growing use of stem cell therapies drive the market.
Moreover, key players are investing in new facilities to enhance their pipeline and production capabilities owing to rising demand for mRNA vaccines and medicines. For instance, in June 2021, Sanofi announced an investment of approximately USD 472.8 million to build the mRNA Center of Excellence to accelerate developing and delivering next-generation vaccines. In addition, in June 2022, Evonik, in partnership with the U.S. government, invested USD 220 million to build a new lipid production facility in the U.S. for mRNA-based therapies. Hence, increasing funding and investments by major players to focus on mRNA research is anticipated to drive market growth.
However, raw materials for mRNA synthesis are the most expensive component for the synthesis of mRNA therapeutics. In addition, these raw materials are new and lack a diversified supply chain, with a limited number of suppliers providing these vital materials. For instance, manufacturing 100 million doses of mRNA-1273 and BNT162b2 was estimated to cost USD 270 million and USD 127.1 million, respectively, thus hampering market growth.
U.S. mRNA Synthesis Raw Materials Market Report Highlights
U.S. mRNA Synthesis Raw Materials Market Growth & Trends
The U.S. mRNA synthesis raw materials market size is anticipated to reach USD 976.2 million by 2030 and is growing at a CAGR of 2.93% from 2024 to 2030, according to a new report by Grand View Research, Inc. The major factors driving the market include growing academic & industrial interest in mRNA technology, advantages of mRNA vaccines, and increasing funding for mRNA research.
The development and widespread application of mRNA vaccines for the COVID-19 disease made 2020 a watershed year for mRNA technology platforms. At the end of 2019, the market value of the five publicly traded mRNA platform companies was over USD 15 billion. This capitalization was about USD 300 billion in August 2021. Recent major investment has been attracted due to the success of mRNA's COVID-19 vaccines, promoting the creation of medications to treat numerous diseases. The upsurge in clinical trials and the growing use of stem cell therapies drive the market.
Moreover, key players are investing in new facilities to enhance their pipeline and production capabilities owing to rising demand for mRNA vaccines and medicines. For instance, in June 2021, Sanofi announced an investment of approximately USD 472.8 million to build the mRNA Center of Excellence to accelerate developing and delivering next-generation vaccines. In addition, in June 2022, Evonik, in partnership with the U.S. government, invested USD 220 million to build a new lipid production facility in the U.S. for mRNA-based therapies. Hence, increasing funding and investments by major players to focus on mRNA research is anticipated to drive market growth.
However, raw materials for mRNA synthesis are the most expensive component for the synthesis of mRNA therapeutics. In addition, these raw materials are new and lack a diversified supply chain, with a limited number of suppliers providing these vital materials. For instance, manufacturing 100 million doses of mRNA-1273 and BNT162b2 was estimated to cost USD 270 million and USD 127.1 million, respectively, thus hampering market growth.
U.S. mRNA Synthesis Raw Materials Market Report Highlights
- Capping agents dominated the type segment with the largest revenue share of 41.02% in 2023. Capping agents function as binding molecules or stabilizers, preventing steric hindrance or agglomeration. Hence, these key functions of capping agents in mRNA synthesis are driving the segment
- Based on the application, vaccine production held the largest revenue market share of 83.86% in 2023. The rising prevalence of chronic diseases, such as cancer, respiratory disorders, cardiac diseases, CKD, and many others, is encouraging scientists to discover novel as well as more effective vaccines using mRNA technology
- Based on end-use, biopharmaceutical & pharmaceutical companies dominated the segment with a revenue share of 49.56% in 2023 and is anticipated to grow at the highest CAGR over the forecast period. This is attributed to the emerging companies in the market entering several collaborations to enhance their mRNA synthesis raw materials offerings
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation and Scope
1.1.1. Type Segment
1.1.2. Application Segment
1.1.3. End-use Segment
1.2. Estimates and Forecast Timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. GVR’s Internal Database
1.4.3. Primary Research
1.5. Information or Data Analysis:
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.8. List of Secondary Sources
1.9. List of Abbreviations
1.10. Objective
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
CHAPTER 3. U.S. MRNA SYNTHESIS RAW MATERIAL MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Growing academic & industrial interest in mRNA technology
3.2.1.2. Advantages of mRNA vaccines
3.2.1.3. Increasing funding for mRNA research
3.2.2. Market Restraint Analysis
3.2.2.1. Nonexistence of effective government regulations for mRNA-based product approvals
3.2.2.2. High cost of mRNA synthesis raw materials
3.2.3. Market Challenge Analysis
3.2.3.1. Lack of long-lasting and affordable manufacturing processes
3.3. Industry Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
CHAPTER 4. U.S. MRNA SYNTHESIS RAW MATERIAL MARKET: TYPE ESTIMATES & TREND ANALYSIS
4.1. Type Segment Dashboard
4.2. U.S. mRNA Synthesis Raw Materials Market Type Movement Analysis
4.3. U.S. mRNA Synthesis Raw Materials Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
4.4. Capping Agents
4.4.1. Capping Agents Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Nucleotides
4.5.1. Nucleotides Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Plasmid DNA
4.6.1. Plasmid DNA Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.7. Enzymes
4.7.1. Enzymes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.7.2. Polymerase
4.7.2.1. Polymerase Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.7.3. RNase Inhibitor
4.7.3.1. RNase Inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.7.4. DNase
4.7.4.1. DNase Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.7.5. Others
4.7.5.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.8. Others
4.8.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 5. U.S. MRNA SYNTHESIS RAW MATERIAL MARKET: APPLICATION ESTIMATES & TREND ANALYSIS
5.1. Application Segment Dashboard
5.2. U.S. mRNA Synthesis Raw Materials Market Application Movement Analysis
5.3. U.S. mRNA Synthesis Raw Materials Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
5.4. Vaccine Production
5.4.1. Vaccine Production Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Therapeutics Production
5.5.1. Therapeutics Production Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Others
5.6.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 6. U.S. MRNA SYNTHESIS RAW MATERIAL MARKET: END-USE ESTIMATES & TREND ANALYSIS
6.1. End-use Segment Dashboard
6.2. U.S. mRNA Synthesis Raw Materials Market End-use Movement Analysis
6.3. U.S. mRNA Synthesis Raw Materials Market Size & Trend Analysis, by End-use, 2018 to 2030 (USD Million)
6.4. Biopharmaceutical & Pharmaceutical Companies
6.4.1. Biopharmaceutical & Pharmaceutical Companies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. CROs & CMOs
6.5.1. CROs & CMOs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. Academic & Research Institutes
6.6.1. Academic & Research Institutes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 7. COMPETITIVE LANDSCAPE
7.1. Company Categorization
7.2. Strategy Mapping
7.3. Company Market Position Analysis, 2023
7.4. Company Profiles/Listing
7.4.1. F. Hoffmann-La Roche Ltd.
7.4.1.1. Overview
7.4.1.2. Financial Performance
7.4.1.3. Product Benchmarking
7.4.1.4. Strategic Initiatives
7.4.2. Jena Bioscience GmbH
7.4.2.1. Overview
7.4.2.2. Financial Performance
7.4.2.3. Product Benchmarking
7.4.2.4. Strategic Initiatives
7.4.3. Merck KGaA
7.4.3.1. Overview
7.4.3.2. Financial Performance
7.4.3.3. Product Benchmarking
7.4.3.4. Strategic Initiatives
7.4.4. Yeasen Biotechnology (Shanghai) Co., Ltd
7.4.4.1. Overview
7.4.4.2. Financial Performance
7.4.4.3. Product Benchmarking
7.4.4.4. Strategic Initiatives
7.4.5. BOC Sciences
7.4.5.1. Overview
7.4.5.2. Financial Performance
7.4.5.3. Product Benchmarking
7.4.5.4. Strategic Initiatives
7.4.6. Thermo Fisher Scientific, Inc.
7.4.6.1. Overview
7.4.6.2. Financial Performance
7.4.6.3. Product Benchmarking
7.4.6.4. Strategic Initiatives
7.4.7. Maravai LifeSciences
7.4.7.1. Overview
7.4.7.2. Financial Performance
7.4.7.3. Product Benchmarking
7.4.7.4. Strategic Initiatives
7.4.8. New England Biolabs
7.4.8.1. Overview
7.4.8.2. Financial Performance
7.4.8.3. Product Benchmarking
7.4.8.4. Strategic Initiatives
7.4.9. Creative Biogene
7.4.9.1. Overview
7.4.9.2. Financial Performance
7.4.9.3. Product Benchmarking
7.4.9.4. Strategic Initiatives
7.4.10. HONGENE
7.4.10.1. Overview
7.4.10.2. Financial Performance
7.4.10.3. Product Benchmarking
7.4.10.4. Strategic Initiatives
7.4.11. Evonik Industries AG
7.4.11.1. Overview
7.4.11.2. Financial Performance
7.4.11.3. Product Benchmarking
7.4.11.4. Strategic Initiatives
7.4.12. GENEVANT SCIENCES CORPORATION
7.4.12.1. Overview
7.4.12.2. Financial Performance
7.4.12.3. Product Benchmarking
7.4.12.4. Strategic Initiatives
1.1. Market Segmentation and Scope
1.1.1. Type Segment
1.1.2. Application Segment
1.1.3. End-use Segment
1.2. Estimates and Forecast Timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. GVR’s Internal Database
1.4.3. Primary Research
1.5. Information or Data Analysis:
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.8. List of Secondary Sources
1.9. List of Abbreviations
1.10. Objective
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
CHAPTER 3. U.S. MRNA SYNTHESIS RAW MATERIAL MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Growing academic & industrial interest in mRNA technology
3.2.1.2. Advantages of mRNA vaccines
3.2.1.3. Increasing funding for mRNA research
3.2.2. Market Restraint Analysis
3.2.2.1. Nonexistence of effective government regulations for mRNA-based product approvals
3.2.2.2. High cost of mRNA synthesis raw materials
3.2.3. Market Challenge Analysis
3.2.3.1. Lack of long-lasting and affordable manufacturing processes
3.3. Industry Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
CHAPTER 4. U.S. MRNA SYNTHESIS RAW MATERIAL MARKET: TYPE ESTIMATES & TREND ANALYSIS
4.1. Type Segment Dashboard
4.2. U.S. mRNA Synthesis Raw Materials Market Type Movement Analysis
4.3. U.S. mRNA Synthesis Raw Materials Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
4.4. Capping Agents
4.4.1. Capping Agents Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Nucleotides
4.5.1. Nucleotides Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Plasmid DNA
4.6.1. Plasmid DNA Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.7. Enzymes
4.7.1. Enzymes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.7.2. Polymerase
4.7.2.1. Polymerase Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.7.3. RNase Inhibitor
4.7.3.1. RNase Inhibitor Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.7.4. DNase
4.7.4.1. DNase Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.7.5. Others
4.7.5.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.8. Others
4.8.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 5. U.S. MRNA SYNTHESIS RAW MATERIAL MARKET: APPLICATION ESTIMATES & TREND ANALYSIS
5.1. Application Segment Dashboard
5.2. U.S. mRNA Synthesis Raw Materials Market Application Movement Analysis
5.3. U.S. mRNA Synthesis Raw Materials Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
5.4. Vaccine Production
5.4.1. Vaccine Production Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Therapeutics Production
5.5.1. Therapeutics Production Market Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Others
5.6.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 6. U.S. MRNA SYNTHESIS RAW MATERIAL MARKET: END-USE ESTIMATES & TREND ANALYSIS
6.1. End-use Segment Dashboard
6.2. U.S. mRNA Synthesis Raw Materials Market End-use Movement Analysis
6.3. U.S. mRNA Synthesis Raw Materials Market Size & Trend Analysis, by End-use, 2018 to 2030 (USD Million)
6.4. Biopharmaceutical & Pharmaceutical Companies
6.4.1. Biopharmaceutical & Pharmaceutical Companies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. CROs & CMOs
6.5.1. CROs & CMOs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. Academic & Research Institutes
6.6.1. Academic & Research Institutes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 7. COMPETITIVE LANDSCAPE
7.1. Company Categorization
7.2. Strategy Mapping
7.3. Company Market Position Analysis, 2023
7.4. Company Profiles/Listing
7.4.1. F. Hoffmann-La Roche Ltd.
7.4.1.1. Overview
7.4.1.2. Financial Performance
7.4.1.3. Product Benchmarking
7.4.1.4. Strategic Initiatives
7.4.2. Jena Bioscience GmbH
7.4.2.1. Overview
7.4.2.2. Financial Performance
7.4.2.3. Product Benchmarking
7.4.2.4. Strategic Initiatives
7.4.3. Merck KGaA
7.4.3.1. Overview
7.4.3.2. Financial Performance
7.4.3.3. Product Benchmarking
7.4.3.4. Strategic Initiatives
7.4.4. Yeasen Biotechnology (Shanghai) Co., Ltd
7.4.4.1. Overview
7.4.4.2. Financial Performance
7.4.4.3. Product Benchmarking
7.4.4.4. Strategic Initiatives
7.4.5. BOC Sciences
7.4.5.1. Overview
7.4.5.2. Financial Performance
7.4.5.3. Product Benchmarking
7.4.5.4. Strategic Initiatives
7.4.6. Thermo Fisher Scientific, Inc.
7.4.6.1. Overview
7.4.6.2. Financial Performance
7.4.6.3. Product Benchmarking
7.4.6.4. Strategic Initiatives
7.4.7. Maravai LifeSciences
7.4.7.1. Overview
7.4.7.2. Financial Performance
7.4.7.3. Product Benchmarking
7.4.7.4. Strategic Initiatives
7.4.8. New England Biolabs
7.4.8.1. Overview
7.4.8.2. Financial Performance
7.4.8.3. Product Benchmarking
7.4.8.4. Strategic Initiatives
7.4.9. Creative Biogene
7.4.9.1. Overview
7.4.9.2. Financial Performance
7.4.9.3. Product Benchmarking
7.4.9.4. Strategic Initiatives
7.4.10. HONGENE
7.4.10.1. Overview
7.4.10.2. Financial Performance
7.4.10.3. Product Benchmarking
7.4.10.4. Strategic Initiatives
7.4.11. Evonik Industries AG
7.4.11.1. Overview
7.4.11.2. Financial Performance
7.4.11.3. Product Benchmarking
7.4.11.4. Strategic Initiatives
7.4.12. GENEVANT SCIENCES CORPORATION
7.4.12.1. Overview
7.4.12.2. Financial Performance
7.4.12.3. Product Benchmarking
7.4.12.4. Strategic Initiatives
LIST OF TABLES
Table 1 List of secondary sources
Table 2 List of abbreviation
Table 3 U.S. mRNA synthesis raw materials market, by type, 2018 - 2030 (USD Million)
Table 4 U.S. mRNA synthesis raw materials market, by application, 2018 - 2030 (USD Million)
Table 5 U.S. mRNA synthesis raw materials market, by end-use, 2018 - 2030 (USD Million)
Table 6 Key companies undergoing expansions
Table 7 Key companies undergoing acquisitions
Table 8 Key companies undergoing collaborations
Table 9 Key companies launching new products/services
Table 10 Key companies undertaking other strategies
Table 1 List of secondary sources
Table 2 List of abbreviation
Table 3 U.S. mRNA synthesis raw materials market, by type, 2018 - 2030 (USD Million)
Table 4 U.S. mRNA synthesis raw materials market, by application, 2018 - 2030 (USD Million)
Table 5 U.S. mRNA synthesis raw materials market, by end-use, 2018 - 2030 (USD Million)
Table 6 Key companies undergoing expansions
Table 7 Key companies undergoing acquisitions
Table 8 Key companies undergoing collaborations
Table 9 Key companies launching new products/services
Table 10 Key companies undertaking other strategies
LIST OF FIGURES
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Market formulation & validation
Fig. 6 U.S. mRNA synthesis raw materials market: market outlook
Fig. 7 U.S. mRNA synthesis raw materials competitive insights
Fig. 8 Parent market outlook
Fig. 9 U.S. mRNA synthesis raw materials market driver impact
Fig. 10 U.S. mRNA synthesis raw materials market restraint impact: Type & services movement analysis
Fig. 11 U.S. mRNA synthesis raw materials market: Type outlook and key takeaways
Fig. 12 Capping agents market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 13 Nucleotides market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 14 Plasmid DNA market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 15 Enzymes market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 16 Polymerase market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 17 RNase inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 18 DNase materials market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 19 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 20 Others market estimates and forecasts,2018 - 2030 (USD Million)
Fig. 21 U.S. mRNA synthesis raw materials market: Application movement analysis
Fig. 22 U.S. mRNA synthesis raw materials market: Application outlook and key takeaways
Fig. 23 Vaccine production market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 24 Therapeutics production market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 25 Others application market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 26 U.S. mRNA synthesis raw materials market: End-use movement analysis
Fig. 27 U.S. mRNA synthesis raw materials market: End-use outlook and key takeaways
Fig. 28 Biopharmaceutical & pharmaceutical companies market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 29 CROs CMOs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 30 Academic & research institutes market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 31 Market share of key market players - U.S. mRNA synthesis raw materials market?
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Market formulation & validation
Fig. 6 U.S. mRNA synthesis raw materials market: market outlook
Fig. 7 U.S. mRNA synthesis raw materials competitive insights
Fig. 8 Parent market outlook
Fig. 9 U.S. mRNA synthesis raw materials market driver impact
Fig. 10 U.S. mRNA synthesis raw materials market restraint impact: Type & services movement analysis
Fig. 11 U.S. mRNA synthesis raw materials market: Type outlook and key takeaways
Fig. 12 Capping agents market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 13 Nucleotides market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 14 Plasmid DNA market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 15 Enzymes market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 16 Polymerase market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 17 RNase inhibitor market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 18 DNase materials market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 19 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 20 Others market estimates and forecasts,2018 - 2030 (USD Million)
Fig. 21 U.S. mRNA synthesis raw materials market: Application movement analysis
Fig. 22 U.S. mRNA synthesis raw materials market: Application outlook and key takeaways
Fig. 23 Vaccine production market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 24 Therapeutics production market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 25 Others application market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 26 U.S. mRNA synthesis raw materials market: End-use movement analysis
Fig. 27 U.S. mRNA synthesis raw materials market: End-use outlook and key takeaways
Fig. 28 Biopharmaceutical & pharmaceutical companies market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 29 CROs CMOs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 30 Academic & research institutes market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 31 Market share of key market players - U.S. mRNA synthesis raw materials market?
